These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 339329)

  • 41. The effect of estramustine phosphate on prostatic cancer estimated by transrectal ultrasonotomography.
    Watanabe H; Ohe H; Ando K; Sawamura Y; Niijima T; Nakamura S; Orikasa S; Tanahashi Y; Imamura K; Yoshida H
    Prostate; 1981; 2(2):155-61. PubMed ID: 7301654
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oral estramustine phosphate (Estracyt): a broad phase II study.
    Halpern J; Catane R
    J Med; 1984; 15(1):35-43. PubMed ID: 6593404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of advanced carcinoma of the prostate with estramustine phosphate.
    Fosså SD; Miller A
    J Urol; 1976 Apr; 115(4):406-8. PubMed ID: 1263316
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Personal experience with treatment of advanced prostatic carcinoma using Estracyt].
    Morávek P
    Rozhl Chir; 1987 Nov; 66(11):749-52. PubMed ID: 3424018
    [No Abstract]   [Full Text] [Related]  

  • 45. Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer.
    Norlén BJ; Andersson SB; Björk P; Gunnarsson PO; Fritjofsson A
    J Urol; 1988 Nov; 140(5):1058-62. PubMed ID: 3172360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
    Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt).
    Gunnarsson PO; Forshell GP; Fritjofsson A; Norlén BJ
    Scand J Urol Nephrol; 1981; 15(3):201-5. PubMed ID: 7323739
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
    Smith PH; Robinson M; Richards B; Suciu S; De Pauw M; Sylvester R; Denis L
    Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
    [No Abstract]   [Full Text] [Related]  

  • 49. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
    Daponte D; Sylvester R; De Pauw M; Fryszman A; Smith RM; Smith PH
    Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The phase IV studies with Estracyt in prostatic cancer--supplementary report: results of long-term therapy].
    Ohhori T; Kubo T; Kawamura S; Suzuki T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
    Hinyokika Kiyo; 1992 Aug; 38(8):979-87. PubMed ID: 1414749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estramustine phosphate in secondary hormone-resistant carcinoma of the prostate.
    Maier U; Hienert G; Simak R
    Eur Urol; 1990; 17(3):216-8. PubMed ID: 2351191
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitory effects of Estracyt on R-3327 rat prostatic carcinoma.
    Müntzing J; Kirdani RY; Saroff J; Murphy GP; Sandberg AA
    Urology; 1977 Nov; 10(5):439-45. PubMed ID: 919134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.
    Boccardo F; Decensi A; Guarneri D; Martorana G; Giberti C; Giuliani L
    Cancer Chemother Pharmacol; 1988; 22(2):172-4. PubMed ID: 3409448
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estracyt--clinical experiences.
    Nilsson T
    Scand J Urol Nephrol Suppl; 1980; 55():135-8. PubMed ID: 6938016
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A current review of the clinical experience with Estracyt.
    Murphy GP
    Prog Clin Biol Res; 1987; 243B():221-5. PubMed ID: 3309982
    [No Abstract]   [Full Text] [Related]  

  • 58. [Stage D1 prostatic cancer benefited by a single regimen of Estracyt].
    Hata M
    Gan To Kagaku Ryoho; 1988 May; 15(5):1787-90. PubMed ID: 3369873
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry.
    Leistenschneider W; Nagel R
    Eur Urol; 1980; 6(2):111-5. PubMed ID: 7358061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estracyt--mode of action and clinical experience.
    Hedlund PO
    Prog Clin Biol Res; 1987; 243B():215-9. PubMed ID: 3309981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.